HCW Biologics Inc.

05/04/2022 | Press release | Archived content

A “kick and expand” strategy to generate large numbers of CIML NK cells for adoptive cell therapy for the treatment of cancer using novel fusion proteins HCW9201 and HCW9206 –[...]

HCW Biologics Inc. published this content on May 04, 2022, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 16, 2025 at 07:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io